RPRX Royalty Pharma Plc Class A

Royalty Pharma Announces Secondary Offering of Class A Ordinary Shares by Selling Shareholders

Royalty Pharma Announces Secondary Offering of Class A Ordinary Shares by Selling Shareholders
EN
13/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Royalty Pharma Plc Class A

 PRESS RELEASE

Royalty Pharma and Revolution Medicines Enter Into Funding Agreements ...

Royalty Pharma and Revolution Medicines Enter Into Funding Agreements for Up to $2 Billion Up to $1.25 billion ($250 million upfront) of synthetic royalty funding and up to $750 million in secured debt Innovative partnership enables Revolution Medicines to retain control over pipeline development and global commercialization of daraxonrasib Highlights Royalty Pharma’s unique ability to provide capital at scale to help leading companies achieve their strategic goalsDaraxonrasib, in Phase 3 development for pancreatic cancer and non-small cell lung cancer, would be the first targeted therapy t...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

 PRESS RELEASE

Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Heal...

Royalty Pharma to Present at the Goldman Sachs 46th Annual Global Healthcare Conference NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 2:00 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at . The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funde...

 PRESS RELEASE

Royalty Pharma Completes the Acquisition of Its External Manager

Royalty Pharma Completes the Acquisition of Its External Manager NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC (“RP Management”). The acquisition received overwhelming support from Royalty Pharma’s shareholders, with 99.9% of votes cast in favor of the transaction. “The completion of the internalization marks an exciting new chapter for Royalty Pharma,” said Pablo Legorreta, founder and Chief Executive Officer. “It reinforces our commitment to transpa...

 PRESS RELEASE

Royalty Pharma to Present at Upcoming Investor Conferences

Royalty Pharma to Present at Upcoming Investor Conferences NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: BofA Securities 2025 Healthcare Conference on Wednesday, May 14 at 5:20 p.m. ET / 2:20 p.m. PTRBC Capital Markets 2025 Global Healthcare Conference on Tuesday, May 20 at 4:05 p.m. ET The webcasts will be accessible from Royalty Pharma’s “Events” page at . Webcasts will also be archived for a minimum of thirty days. About Royalty Pharma Fou...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch